17. Apr 2018 Datwyler at INTERPHEX 2018: “The US is a key market for pharmaceutical manufacturing”

 Datwyler, the Swiss-based industrial supplier of state-of-the-art solutions for drug packaging an medical devices, will participate as an exhibitor at the 2018 INTERPHEX in New York. Datwyler is currently building a new production facility in Middletown, Delaware, which is scheduled to start production in the second half of 2018. It will be the company’s second US-based operation for its Health Care business and will incorporate state-of-the-art cleanroom manufacturing in accordance with the company’s own First Line standard.

“The decision to open a new facility in the mid-Atlantic area of the United States – a pharmaceutical hotbed –caters to current trends and developments in the pharmaceutical industry”, underlines Glenn Thorpe, Senior Vice President Parenteral Packaging Systems. “Especially with regards to cleanroom manufacturing, which will become even more important in the years to come. Current and future patient safety, as one of the most crucial factors for the pharmaceutical industry, relies to a great extent on high-tech drug administration solutions and technologies which are more and more produced in a cleanroom environment.”

Datwyler produces over 16 billion high-quality components for health care applications each year. By entering emerging markets, leveraging lean production processes, and building upon an optimized supply chain,Datwyler is prepared to master the challenges of the global health care industry. Next to showcasing state-ofthe-art products and sealing solutions portfolio for the pharmaceutical industry at the 2018 INTERPHEX,Datwyler experts are also looking forward to sharing new developments of the company’s overall strategy and expansion plans for strengthening its position in the U.S., the world’s largest pharmaceutical market.

Strengthening Datwyler’s position in the U.S. pharmaceutical market
Datwyler is channelling more than $100 million into the new facility in Middletown, Delaware, which is planned,designed and built in accordance with Datwyler’s latest First Line standard. With production scheduled to start in September 2018, the new facility will manufacture high-quality elastomer components for injectable drug delivery systems. Once it is fully up and running, the highly automated plant will provide jobs for around 120 employees. This investment will enable Datwyler to better provide customers in its three key business regions,the U.S., Europe and Asia, with locally produced components of the highest quality – now, and in the future.

Commitment to the highest level of quality
Pharmaceutical and medical manufacturers rely on partners with a deep understanding of not only the
industry’s challenges and requirements, but also its opportunities and promise for growth and development.Datwyler will leverage both its superior expertise and its strong sense for future trends in order to advance global health care. Datwyler’s production standard First Line, which will be applied in the Delaware facility, is specially designed to manufacture pharmaceutical elastomer components in a fully integrated good manufacturing practice (GMP) environment conforming to the highest industry standards. This innovative approach to manufacturing exceeds the most stringent quality standards of the European and US regulatory authorities and is certified to ISO 15378. The production standard is dedicated to guaranteeing the greatest quality and safety for pharmaceutical components. Datwyler stands for the ongoing commitment to the highest levels of quality. Because we care.

The Datwyler Group is an international supplier of state-of-the-art industrial components with leading positions in global and regional market segments. As technological leader, the Datwyler Group delivers added value to its customers in all markets served. In its Sealing Solutions division, Datwyler provides customised sealing solutions to manufacturers and companies which operate in the health care and automotive industry, as well as the market segments civil engineering and consumer goods. Within the health care unit, Datwyler develops,designs and manufactures solutions for injectable packaging and drug delivery systems to facilitate customers to create a safer medical environment of tomorrow. The company develops complex and unique coatings and rubber compounds enabling customers to fill syringes with medicine and thus gives numerous people across the globe access to new medications. The products and services of Datwyler are built on high-quality material,innovative technologies, outstanding engineering and process know-how. With a global manufacturing footprint on three continents, sales in over 100 countries and more than 7,000 employees, the Datwyler Group generates an annual revenue in excess of € 1’200 million. Looking back onto more than 100 years of history, Datwyler is a reliable partner, now and in the future.

Datwyler Sealing Solutions: Simone Ramser, Vice President Communications,
simone.ramser@datwyler.com, +41 41 875 1410
Burson-Marsteller GmbH, Amelie Mayer-Quien, amelie.mayer-quien@bm.com, +49 69 238 0967
Photos (in print quality): http://www.datwyler.com/en/media/image-library/